MannKind is trading 5.1% down at $3.56 as broader biotech weakness pressures commercial-stage drugmakers.
- The biotech sector is down 2.11% as investors react to disappointing industry clinical-trial news and reduced enthusiasm for biotech M&A.
- MannKind’s September 15 H.C. Wainwright presentation was generally positive, but management offered no formal 2027 revenue guidance and acknowledged that commercial traction remains unproven.
- No company-specific negative catalyst was reported.